Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 2021 Mar 22

PMID 33751415

Citations 16

Authors

Jan-Willem Alffenaar

Anne-Grete Martson

Scott K Heysell

Jin-Gun Cho

Asad Patanwala

Gina Burch

Hannah Y Kim

Marieke G G Sturkenboom

Anthony Byrne

Debbie Marriott

Indy Sandaradura

Simon Tiberi

Vitali Sintchencko

Shashikant Srivastava

Charles A Peloquin

Affiliations

Soon will be listed here.

Abstract

Nontuberculous mycobacteria can cause minimally symptomatic self-limiting infections to progressive and life-threatening disease of multiple organs. Several factors such as increased testing and prevalence have made this an emerging infectious disease. Multiple guidelines have been published to guide therapy, which remains difficult owing to the complexity of therapy, the potential for acquired resistance, the toxicity of treatment, and a high treatment failure rate. Given the long duration of therapy, complex multi-drug treatment regimens, and the risk of drug toxicity, therapeutic drug monitoring is an excellent method to optimize treatment. However, currently, there is little available guidance on therapeutic drug monitoring for this condition. The aim of this review is to provide information on the pharmacokinetic/pharmacodynamic targets for individual drugs used in the treatment of nontuberculous mycobacteria disease. Lacking data from randomized controlled trials, in vitro, in vivo, and clinical data were aggregated to facilitate recommendations for therapeutic drug monitoring to improve efficacy and reduce toxicity.

Citing Articles

Semisynthesis, Structure Elucidation and Anti- Activity of a Series of Marine-Derived 14-Membered Resorcylic Acid Lactones with Interesting Ketal Groups.

Yin J, Wang C, Zhang X, Cheng Y, Wu Y, Zhang Q Mar Drugs. 2024; 22(10).

PMID: 39452839 PMC: 11509596. DOI: 10.3390/md22100431.

Prescription habits and drugs accessibility for the treatment of non-tuberculous mycobacteria infections in Italy: a multicentric survey from the IRENE study group.

Stroffolini G, Lupia T, Gaviraghi A, Venuti F, Cinnirella G, Gori A Infection. 2024; 53(1):383-392.

PMID: 39302627 PMC: 11825620. DOI: 10.1007/s15010-024-02390-y.

Combination of Imipenem-Cilastatin-Relebactam and Amoxicillin in the Antibiotic Regimen in Two Cases of Mycobacterium abscessus Lung Infection.

Vogiatzoglou A, Hadji Mitrova M, Papadaki E, Sionidou M, Nikopoulou A, Kontos F Cureus. 2024; 16(7):e65112.

PMID: 39171000 PMC: 11338295. DOI: 10.7759/cureus.65112.

Drinking Water Microbiota, Entero-Mammary Pathways, and Breast Cancer: Focus on Nontuberculous Mycobacteria.

Maranha A, Alarico S, Nunes-Costa D, Melo-Marques I, Roxo I, Castanheira P Microorganisms. 2024; 12(7).

PMID: 39065193 PMC: 11279143. DOI: 10.3390/microorganisms12071425.

Applications and advances in molecular diagnostics: revolutionizing non-tuberculous mycobacteria species and subspecies identification.

Zhang H, Tang M, Li D, Xu M, Ao Y, Lin L Front Public Health. 2024; 12:1410672.

PMID: 38962772 PMC: 11220129. DOI: 10.3389/fpubh.2024.1410672.

References

Mouton J, Vinks A . Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet. 2005; 44(2):201-10. DOI: 10.2165/00003088-200544020-00005. View

Cowman S, van Ingen J, Griffith D, Loebinger M . Non-tuberculous mycobacterial pulmonary disease. Eur Respir J. 2019; 54(1). DOI: 10.1183/13993003.00250-2019. View

Srivastava S, Deshpande D, Gumbo T . Failure of the azithromycin and ethambutol combination regimen in the hollow-fibre system model of pulmonary Mycobacterium avium infection is due to acquired resistance. J Antimicrob Chemother. 2017; 72(suppl_2):i20-i23. PMC: 5890692. DOI: 10.1093/jac/dkx303. View

Srivastava S, Gumbo T . Clofazimine for the Treatment of Mycobacterium kansasii. Antimicrob Agents Chemother. 2018; 62(8). PMC: 6105821. DOI: 10.1128/AAC.00248-18. View

Rominski A, Schulthess B, Muller D, Keller P, Sander P . Effect of β-lactamase production and β-lactam instability on MIC testing results for Mycobacterium abscessus. J Antimicrob Chemother. 2017; 72(11):3070-3078. DOI: 10.1093/jac/dkx284. View

Ferro B, Srivastava S, Deshpande D, Pasipanodya J, van Soolingen D, Mouton J . Moxifloxacin's Limited Efficacy in the Hollow-Fiber Model of Mycobacterium abscessus Disease. Antimicrob Agents Chemother. 2016; 60(6):3779-85. PMC: 4879399. DOI: 10.1128/AAC.02821-15. View

Chapagain M, Gumbo T, Heysell S, Srivastava S . Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. Antimicrob Agents Chemother. 2020; 64(10). PMC: 7508568. DOI: 10.1128/AAC.00810-20. View

Hoefsloot W, van Ingen J, Andrejak C, Angeby K, Bauriaud R, Bemer P . The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J. 2013; 42(6):1604-13. DOI: 10.1183/09031936.00149212. View

Abdelwahab M, Wasserman S, Brust J, Gandhi N, Meintjes G, Everitt D . Clofazimine pharmacokinetics in patients with TB: dosing implications. J Antimicrob Chemother. 2020; 75(11):3269-3277. PMC: 7566350. DOI: 10.1093/jac/dkaa310. View

10.

Ashizawa N, Tsuji Y, Kawago K, Higashi Y, Tashiro M, Nogami M . Successful treatment of methicillin-resistant Staphylococcus aureus osteomyelitis with combination therapy using linezolid and rifampicin under therapeutic drug monitoring. J Infect Chemother. 2016; 22(5):331-4. DOI: 10.1016/j.jiac.2015.11.012. View

11.

Wehrli W . Rifampin: mechanisms of action and resistance. Rev Infect Dis. 1983; 5 Suppl 3:S407-11. DOI: 10.1093/clinids/5.supplement_3.s407. View

12.

Srivastava S, Pasipanodya J, Sherman C, Meek C, Leff R, Gumbo T . Rapid drug tolerance and dramatic sterilizing effect of moxifloxacin monotherapy in a novel hollow-fiber model of intracellular Mycobacterium kansasii disease. Antimicrob Agents Chemother. 2015; 59(4):2273-9. PMC: 4356829. DOI: 10.1128/AAC.04441-14. View

13.

Stott K, Pertinez H, Sturkenboom M, Boeree M, Aarnoutse R, Ramachandran G . Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother. 2018; 73(9):2305-2313. PMC: 6105874. DOI: 10.1093/jac/dky152. View

14.

Ceyssens P, Soetaert K, Timke M, Van den Bossche A, Sparbier K, De Cremer K . Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Combined Species Identification and Drug Sensitivity Testing in Mycobacteria. J Clin Microbiol. 2016; 55(2):624-634. PMC: 5277533. DOI: 10.1128/JCM.02089-16. View

15.

Gumbo T, Angulo-Barturen I, Ferrer-Bazaga S . Pharmacokinetic-pharmacodynamic and dose-response relationships of antituberculosis drugs: recommendations and standards for industry and academia. J Infect Dis. 2015; 211 Suppl 3:S96-S106. DOI: 10.1093/infdis/jiu610. View

16.

Moon S, Park H, Kim S, Jhun B, Lee H, Jeon K . Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2016; 60(11):6758-6765. PMC: 5075083. DOI: 10.1128/AAC.01240-16. View

17.

Bolhuis M, van Altena R, van Soolingen D, de Lange W, Uges D, van der Werf T . Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients. Eur Respir J. 2013; 42(6):1614-21. DOI: 10.1183/09031936.00001913. View

18.

Gilljam M, Berning S, Peloquin C, Strandvik B, Larsson L . Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J. 1999; 14(2):347-51. DOI: 10.1034/j.1399-3003.1999.14b18.x. View

19.

Srivastava S, Gumbo T . In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens. Curr Pharm Des. 2011; 17(27):2881-8. DOI: 10.2174/138161211797470192. View

20.

Zuckerman J, Qamar F, Bono B . Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am. 2011; 95(4):761-91, viii. DOI: 10.1016/j.mcna.2011.03.012. View